Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The stock's rise snapped a three-day losing streak.

Barclays analyst Stephanie Davis maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $616.00. The company’s shares closed yesterday at $514.75.

San Francisco, CA-based McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: MCK boasts a Value Style Score of A and VGM Score ...

Shares of McKesson (MCK) are oversold. They are also at a potential support level. Stocks that are oversold and at support tend to rally. The best traders traders focus on key price levels and ...

(Bloomberg) -- Several publicly traded drug distributors are vying to buy Florida Cancer Specialists & Research Institute, a privately held operator of oncology clinics, people familiar with the ...

Baird downgraded medical distributor McKesson (NYSE:MCK) to neutral from outperform on Tuesday, calling the company's plans to conduct an investor event with the sell-side community "unusual." ...

The purchases in question are McKesson Corporation’s $2.5 billion bid for a controlling stake in the Florida Cancer Specialists & Research Institute’s management services organization ...

McKesson (MCK) closed at $488.78 in the latest trading session, marking a -1.95% move from the prior day. This change lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow saw an upswing of ...

Issue: Whether the Hobbs Act required the district court in this case to accept the Federal Communications Commission’s legal interpretation of the Telephone Consumer Protection Act. Jun 18 2024 ...